Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Novartis Announces FDA Filing Acceptance and Priority Review of Brolucizumab (RTH258) for Patients with Wet AMD

drugsApril 17, 2019

Tag: FDA , Novartis , AMD , brolucizumab , RTH258

PharmaSources Customer Service